Asthma is considered to be one of the most common diseases affecting the population in the world, and it is also a life-threatening disease that affects the normal breathing of patients. Asthma has a very strong research pipeline, and there are several drug candidates in the late and mid stages of development. There are also several double and triple inhalers in the late development stage of asthma, aimed at increasing compliance rates.
Las Vegas, USA, October 20, 2021 (GLOBE NEWSWIRE) - An unusually robust asthma pipeline with more than 100 pipeline therapies has broadly promoted the research field of lung diseases
Asthma is considered to be one of the most common diseases affecting the population in the world, and it is also a life-threatening disease that affects the normal breathing of patients. Asthma has a very powerful research pipeline, with several candidates in the late and mid-stage of development. There are also several double and triple inhalers in the late development stage of asthma, aimed at increasing compliance rates.
DelveInsight's "Asthma Pipeline Insight 2021" report covers in detail the available, marketed and pipeline therapies at different stages of clinical development, major pharmaceutical companies committed to advancing the pipeline space, and the future growth potential of the asthma pipeline field.
Some important contents of the Asthma Pipeline report:
DelveInsight's asthma pipeline analysis depicts a powerful space with more than 100 active participants working to develop more than 100 pipeline treatment therapies.
Some major pharmaceutical companies working on developing potential drug candidates to improve asthma treatment options include Amgen, GlaxoSmithKline, Equillium, Viatris, Synermore Biologics, Tarus Therapeutics, Siolta Therapeutics, Chiesi Farmaceutici, Regeneron Pharmaceuticals, EURRUS Biotech, Palobiofarma SL, 4D plc, AB Science, Pearl Therapeutics, Avillion, Novartis, Celltrion, AstraZeneca, Atopix Therapeutics, Glenmark Pharmaceuticals, EMS, Biohaven Pharmaceuticals, Inc., Teva Pharmaceutical, TFF Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, Inc., CSL Behring, Oneness Biotech Co., Ltd., Aldeyra Therapeutics, Inc., Shanghai Biomabs Pharmaceutical Co., Ltd. Evelo Biosciences, Inc, Atridia Pty Ltd., Keymed Biosciences Co. Ltd, etc.
Basic asthma therapy, such as Tezepelumab, Depemokimab, MG 01/T 517, Masitinib, BGF MDI, NOV-14, FB704A, TEV-53275, ADX-629, FP-025, SelK2, MRx-4DP0004, AQ001S- 1703, A2BR inhibitor, PR103, KN-002, TQC2731, Zavegepant, MTPS9579A, CM326, ZL-2102, Dexpramipexole, VR588, etc. are developing clinical trials in different stages.
Tezepelumab is a research and potentially first-class human monoclonal antibody that can act on the main source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental pollution. The U.S. Food and Drug Administration (FDA) has received priority review of a Biologics Licensing Application (BLA) for tezepelumab for the treatment of patients with severe asthma.
GSK'294 is an investigational drug, which may become the first biological agent to produce long-term IL-5 inhibition in SEA patients by subcutaneous injection every six months. GalaxoSmithKline was administered to the first patient in March 2021 to evaluate the effect of GSK 294 in the treatment of severe eosinophilic asthma (SEA).
The UK-based Vectura Group and Kinaset Therapeutics have reached an agreement on the development and commercialization of VR588, an inhaled pan-JAK inhibitor for the treatment of severe asthma. The drug is currently being evaluated in phase I clinical trials.
In April 2020, Leo Pharmaceuticals signed a licensing agreement with Oneness Biotech and Microbio Shanghai on the new atopic dermatitis and asthma drug candidate FB825
Aslan Pharma's product portfolio is led by ASLAN004, a new first-class antibody against IL-13 receptor, which may become the best disease for the treatment of atopic dermatitis and asthma.
In September 2021, the fixed-dose combination of salbutamol/budesonide showed promising results in phase III clinical trials.
Masitinib is another potential pipeline therapy for asthma and is being studied for the treatment of severe asthma that cannot be controlled by oral corticosteroids (OCS) and severe asthma that cannot be controlled by high-dose inhaled corticosteroids (ICS). According to reports, Masitinib has achieved positive phase III results in severe asthma that cannot be controlled by oral corticosteroids.
Request samples and learn more about the reported products @ Asthma Emerging Therapies
The Asthma Pipeline report details the pipeline assets, the comparative analysis of clinical and non-clinical asthma products, the comprehensive assessment of inactive and dormant assets, driving and inhibitory factors, and the opportunities and risks in the asthma pipeline landscape.
Asthma is a long-term disease that affects children and adults. Due to inflammation and tightening of the muscles around the small airways, the airways in the lungs become narrow. This can cause asthma symptoms: coughing, wheezing, shortness of breath and chest tightness.
The triggers for asthma vary from person to person, but may include viral infections (colds), dust, smoke, smog, weather changes, grass and tree pollen, animal fur and feathers, strong soaps and perfumes.
Learn more about this disease and its recent developments @Asthma Pipeline Assessment
Adenosine A2B receptor antagonist
Learn more about the new type of asthma pipeline therapies @ asthma pipeline analysis
The Asthma Pipeline report provides a holistic view of emerging new therapies for asthma broken down by stage, product type, molecular type, mechanism of action, and route of administration.
Adenosine A2B receptor antagonist
Scope of Asthma Pipeline Report
Main participants: Amgen, GlaxoSmithKline, Equillium, Viatris, Synermore Biologics, Tarus Therapeutics, Siolta Therapeutics, Chiesi Farmaceutici, Regeneron Pharmaceuticals, EURRUS Biotech, Palobiofarma SL, 4D Pharma plc, AB Science, Pearl Therapeutics, Novartis, Avillion Atopix Therapeutics, Glenmark Pharmaceuticals, EMS, Biohaven Pharmaceuticals, Inc., Teva Pharmaceutical, TFF Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, Inc., CSL Behring, Oneness Biotech Co., Ltd., Aldeyra Therapeutics , Inc., Shanghai Biomabs Pharmaceutical Co., Ltd., Suzhou Connect Biopharmaceuticals, Ltd., Kinaset Therapeutics Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Evelo Biosciences, Inc, Atridia Pty Ltd., Keymed Biosciences Co. Ltd, and others.
Main asthma pipeline therapy: Tezepelumab, Depemokimab, MG 01/T 517, Masitinib, BGF MDI, NOV-14, FB704A, TEV-53275, ADX-629, FP-025, SelK2, MRx-4DP0004, SQ0001 1703, A2BR Inhibitors, PR103, KN-002, TQC2731, Zavegepant, MTPS9579A, CM326, ZL-2102, Dexpramipexole, VR588, etc.
For more insights on emerging therapies and evaluations, please visit @Asthma Emerging Therapies
Asthma-the analytical perspective of DelveInsight
Mid-term product (Phase II)
Early product (Phase 1)
Pre-clinical and discovery stage products
Research Project: A2BR Inhibitor: Tarus Therapeutics
Asthma-market drivers and barriers
Asthma-future outlook and conclusions
For more information about current pipeline treatments for asthma, please contact @ asthma ongoing clinical trials
Track and evaluate candidates' clinical development process through actionable intelligence and comparative treatment evaluation
DelveInsight's "Idiopathic Pulmonary Fibrosis-Pipeline Insights 2021" report provides comprehensive insights into more than 75 companies and more than 75 pipeline drugs in the field of idiopathic pulmonary fibrosis pipelines. It covers pipeline drug profiles, including clinical and non-clinical stage products and key companies involved, such as FibroGen, Vicore Pharma, Boehringer Ingelheim, AstraZeneca, Avalyn Pharmaceuticals, Indalo Therapeutics, Biosplice Therapeutics, Kinarus, CohBar, Reviva Biopharmaceuticals , J2H Biotech, Translate Bio, Daewoong Pharmaceutical, Roche, etc.
Acute Respiratory Distress Syndrome Tube
DelveInsight's "Acute Respiratory Distress Syndrome-Pipeline Insight 2021" report provides comprehensive insights into more than 60 companies and more than 60 pipeline drugs in the acute respiratory distress syndrome pipeline field. It covers pipeline drug profiles, including clinical and non-clinical stage products and key companies involved, such as Faron Pharmaceuticals, BioMck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, etc.
Chronic obstructive pulmonary disease pipeline
DelveInsight's "Chronic Obstructive Pulmonary Disease-Pipeline Insights 2021" report provides comprehensive insights into more than 50 companies and more than 50 pipeline drugs in the chronic obstructive pulmonary disease pipeline field. It covers pipeline drug profiles, including clinical and non-clinical stage products, and key companies involved, such as GlaxoSmithKline, Sanofi, Chiesi Farmaceutici SpA, United Therapeutics, Verona Pharmaceuticals, AstraZeneca, Immunotek , Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, etc.
DelveInsight's "Interstitial Lung Disease-Pipeline Insights 2021" report provides comprehensive insights into more than 100 companies and more than 100 pipeline drugs in the interstitial lung disease pipeline. It covers pipeline drug profiles, including clinical and non-clinical stage products and key companies involved, such as AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Dadi Pharmaceuticals, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Blade Therapeutics, Acceleron Pharma, etc.
DelveInsight's "Artificial Lung Equipment-Pipeline Insights and Competitive Landscape, 2021" report provides comprehensive insights on more than 20 companies and 23 pipeline equipment in the artificial lung equipment pipeline landscape, including Lung Biotechnology, Miromatrix, Charles Stark Draper Key companies such as Laboratory Inc, United Therapeutics Corporation, XVIVO Perfusion, Medtronic, Getinge, Xenios AG, ALung Technologies Inc., MC3 Cardiopulmonary, Abiomed, etc.
DelveInsight's "Asthma Market Insights, Epidemiology and Market Forecasts in 2030" report provides in-depth understanding of asthma, historical and predicted epidemiology, market drivers, market barriers and unmet medical needs to grasp the best opportunities and evaluate Potential market.
Allergic asthma caused by dust mite market
DelveInsight's "Allergic Asthma Caused by Acaroid Mites-Market Insights, Epidemiology and Market Forecast-2030" report provides in-depth understanding of allergic asthma caused by Acaroid mites, historical and predicted epidemiology, and current allergies caused by Acaroid treatments Asthma/algorithms, market drivers, market barriers and unmet medical needs to plan the best opportunities and assess the potential potential of the market.
DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology and Market Forecast 2030" report provides in-depth understanding of eosinophilic asthma, historical and predicted epidemiology, market drivers, market barriers and unmet medical needs to plan the best opportunities And assess the potential potential of the market.
DelveInsight's "Asthma-Epidemiological Forecasts to 2030" report provides an in-depth understanding of the disease, history, and predicted asthma epidemiology in 7MM, namely the United States, the European Union 5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Browse our blog posts
Asthma: Increasing prevalence and major management challenges. In the past three to four years, the morbidity and mortality caused by asthma have increased significantly.
The alarming growth of chronic respiratory disease (CRD) and its long-term impact on quality of life Today, the increasing prevalence of chronic respiratory disease (CRD) is one of the major health challenges worldwide. CRD affects hundreds of millions of people and causes huge mortality, morbidity, huge socioeconomic burden and disability-adjusted life years (DALY).
The 7 leading pharmaceutical companies in the pharmaceutical industry in 2020 pharmaceutical companies play a vital role in our lives and in helping us lead healthier lives. The pharmaceutical industry seeks, develops, manufactures and promotes drugs or medicines.
DelveInsight is a leading business consultant and market research company, focusing on life sciences. It provides support to pharmaceutical companies by providing comprehensive end-to-end solutions to improve the performance of pharmaceutical companies. Easily access all healthcare and pharmaceutical market research reports through our subscription-based platform PharmDelve.
For more insights, please visit Pharmaceutical, Healthcare and Biotechnology News
As of 12:35 pm Eastern Time on Tuesday, Novavax (NASDAQ: NVAX) shares have soared 24.1%. The head of the European Medicines Agency, Emma Cook, told the EU Minister of Health on Tuesday that Novavax's COVID-19 vaccine may be approved in the "near future." In addition, a study led by the University of Oxford found that after the initial dose of the AstraZeneca (NASDAQ: AZN) vaccine, a second dose of Novavax was more effective than two doses of AstraZeneca.
These companies produce the only important thing.
Apple shares rose 3.5% on Tuesday to a record closing price of $171.18, after an analyst set the stock's target price to a new high as Wall Street expected. Morgan Stanley analyst Katie Huberty now expects Apple's stock price to rise to $200, higher than the previous forecast of $164. Huberty believes that as the volatility of the financial market has returned and traders look for quality companies that are considered safer investments, Apple's stock price will rise.
Wood had made crazier calls before, and her money was right.
Apple did not immediately respond to Reuters' request for comment. The report cited interviews and internal Apple documents as saying that the five-year agreement was reached when Cook visited China in 2016 to cancel a series of regulatory actions against the company. The report added that Cook lobbied Chinese officials who believed that the company had made insufficient contributions to the local economy and signed agreements with Chinese government agencies to make concessions to Beijing and win key legal exemptions.
As Apple's share price hit a record high, the Dow Jones index rose. After CEO Elon Musk lashed out, Tesla's stock skyrocketed. Donald Trump's SPAC soared.
Hydrogen fuel cell stocks opened strongly on Tuesday, with Plug Power (NASDAQ: PLUG), Bloom Energy (NYSE: BE) and Nikola (NASDAQ: NKLA) up 7.7%, 7% and 5.7%, respectively, at 2:25 PM Eastern Time. A number of developments confirmed the growing global interest in green hydrogen and fuel cell technology, rekindling investor interest in today’s leading hydrogen stocks. At the same time, the United Arab Emirates (UAE) is cooperating with French utility company Engie to invest US$5 billion to develop renewable energy and hydrogen projects with a capacity of 2 gigawatts by 2030.
Hundreds of Chinese companies are listed on the U.S. market. But, which are the Chinese stocks worth buying or paying attention to? JD.com, Weilai, Liqi, Xiaopeng and BYD. China is the world's most populous country and the second largest economy. The urban middle class is booming and entrepreneurial activities are amazing.
With the steady reopening of the economy, Matthew Lynn said that one of the unintended consequences of the pandemic is that older workers choose not to return to work, but to live a comfortable life by saving and investing. This is a "great retirement."
Insider Monkey has processed a large number of 13F files of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F document shows the positions of hedge funds and successful investors as of the end of the third quarter. You can find articles about individual hedge fund transactions on numerous financial [...]
In this article, we will discuss the 10 best hydrogen fuel stocks to buy today. If you want to skip our detailed analysis of these stocks, please go directly to the 5 hydrogen fuel cell stocks to buy today. Hydrogen fuel is an attractive source for power generation, transportation, household and industrial applications because it is […]
After the African e-commerce market announced some key indicators of its Black Friday sales period, the stock price of Jumia Technologies (NYSE: JMIA) soared 20.8% on Tuesday. Between November 5 and November 30, Jumia's gross merchandise (GMV)—essentially the total value of transactions on its platform—increased by 30% year-on-year to $150 million. Unique visitors to the Jumia website increased by 27% to nearly 40 million, and orders increased by 39% to 4.3 million, driving this growth.
(Bloomberg)-Jeffrey Gundlach believes that financial markets will face "turbulent waves" because the Fed is preparing to accelerate the end of its quantitative easing policy and then turn to raising interest rates. Most of the articles from Bloomberg, the world's relentless demand for chips became deadly in Malaysia
The past month or so has been bad for fintech stocks, but on Tuesday, as investors began to shake off concerns about the potential risks posed by the omicron COVID-19 variant, they changed course. On the day when the Nasdaq Composite Index rose 3%, Upstart (NASDAQ: UPST) rose about 10%, LendingClub (NYSE: LC) rose about 8%, and Katapult (NASDAQ: (Stock code: KPLT) rose 14.3%. This fall, people are even more worried that inflation will be stronger and last longer than experts had previously expected.
According to FactSet's data, GameStop expects an adjusted net loss of 52 cents per share for the third fiscal quarter and sales of $1.19 billion.
Lucid (LCID) shares fell 12% at the start of trading on Monday after the high-end electric car startup revealed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its recent cooperation with a special purpose acquisition company.
As of 12:51 pm Eastern Time, Moderna's (NASDAQ: MRNA) share price has risen 3.1%. After announcing the results of the COVID-19 vaccine research led by the University of Oxford, gains were made. This study found that after the first dose of Pfizer-BioNTech vaccine or AstraZeneca vaccine, the second dose of Moderna's vaccine was more effective than two doses of the other two vaccines.
Meme stock outperformed the market on Tuesday, and investors look forward to GameStop's next quarterly report released on Wednesday.
In this article, we will use hedge fund sentiment as a tool and determine whether Moderna, Inc. (NASDAQ: MRNA) is currently a good investment. We like to analyze the sentiment of hedge funds before doing a few days of in-depth research. We do this because hedge funds and other elite investors have many Ivy League graduates and experts [...]
Due to regulatory pressures and signs of slowing growth, the Chinese technology giant's market value has shrunk by nearly a quarter in the past month.